High cumulative JC virus seroconversion rate during long-term use of natalizumab.
about
The use of natalizumab for multiple sclerosisStability and predictive value of anti-JCV antibody index in multiple sclerosis: A 6-year longitudinal study.JCV serology in time: 3 years of follow-up.Diagnosis and Treatment of Progressive Multifocal Leukoencephalopathy Associated with Multiple Sclerosis Therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Anti-JCV serology during natalizumab treatment: Review and meta-analysis of 17 independent patient cohorts analyzing anti-John Cunningham polyoma virus sero-conversion rates under natalizumab treatment and differences between technical and biologicaJohn Cunningham virus conversion in relation to natalizumab concentration in multiple sclerosis patients.Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.The clinical utility of JC virus antibody index measurements in the context of progressive multifocal leukoencephalopathy.Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica.Therapy of highly active pediatric multiple sclerosis.Advances and insights into neurological practice 2016-17.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphatImpact of Disease-Modifying Treatments on the Longitudinal Evolution of Anti-JCV Antibody Index in Multiple Sclerosis
P2860
Q33879159-AF956068-F8A2-405D-A183-46CDE0B97733Q36314901-B895C70A-65AC-4E90-9D0D-A3CB46255D5FQ39263983-3183A659-8862-4E3B-94EA-073B198F32FDQ40039520-2F8755D6-6627-4555-982F-312121E5C56DQ40061894-5B1035B5-4F5F-43C5-8C1F-1B1511592EC4Q40067748-9647A0E6-8498-46DC-8459-907105F157BDQ40122994-BD3FD5A6-3F60-48F0-986C-C059A78D6B20Q40401876-BC47A7B2-F2BB-4CFA-A203-63D0A8692235Q45325710-12FFDDD7-796F-450D-9DED-5DBAE02E2B0AQ47548881-45DCE5FF-7EC5-4437-9F6B-60642698BA39Q49968003-FA6DBF98-AB69-4A17-B58B-EA56310B42EBQ50072374-E48DD6F0-86ED-476D-8A99-A41AB97F74DEQ50086043-E1AA9C71-B027-4435-AECE-D3C8C3ADF08EQ58556268-FF246754-63FE-413F-A422-24F6BEB61FD9
P2860
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@en
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@nl
type
label
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@en
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@nl
prefLabel
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@en
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@nl
P2093
P2860
P356
P1476
High cumulative JC virus seroconversion rate during long-term use of natalizumab.
@en
P2093
A Vennegoor
B M J Uitdehaag
J A van Rossum
J Killestein
J L A N Murk
M P Wattjes
P2860
P304
P356
10.1111/ENE.12988
P577
2016-03-27T00:00:00Z